In this interview Janet Manzo, Executive Director of the Ontario Cancer Research Ethics Board, discusses the development of a province-wide…
Scimega Oncology, (www.scimega.com) the company behind the revolutionary Reverse Feasibility Program, announced it has been awarded
Those of us who work in clinical operations and oncology drug development can sometimes get caught up in the operations or science and lose sight of the impact our work can have on the lives of people battling cancer. I’d like to share one man’s story to illustrate
A biotech sponsor in the United States had targeted July 2015 for completion of enrollment for a Phase I dose-finding HER2+BrCa study.
Over the last decade, increased competition for finite patient populations in the U.S. have led many drug developers to expand…
In this interview, Marjorie Morrison, CEO of the Canadian Cancer Action Network, talks about the important role patient advocacy groups…
In this interview, conducted by Keystone Marketing's Scott Broady, Denise Deakin, Co-Founder & President of Scimega Oncology answers questions about…
During a recent meeting with a sponsor, I was asked whether our clinical research associates (CRAs) were assigned by site,…
I sat down recently with three of our Oncology Leads and asked them what questions they hear most often from…
In this interview Penny Chipman, Manager of the Clinical Research Program at the Gerald Bronfman Centre for Clinical Research in…